Dual control of chronic plaque psoriasis and pouchitis with tildrakizumab

We report the first documented case of concurrent remission of chronic plaque psoriasis and pouchitis with tildrakizumab therapy. A 66-year-old man achieved sustained psoriasis clearance and pouchitis improvement following interleukin (IL)-23p19 inhibition, after an inadequate response to ultraviolet therapy, ciclosporin and adalimumab. This case highlights the potential role of selective IL-23 blockade in managing coexisting immune-mediated inflammatory conditions.